tutorial

Intimal Sarcoma Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting intimal sarcoma care, covering vascular imaging surveillance pipelines, MDM2 molecular diagnostic workflows, thromboembolic event detection, surgical and endovascular procedure coordination, and multidisciplinary tumor board automation for this rare intravascular malignancy."

Intimal Sarcoma Care Tech Platform Monitoring Guide 2026

Overview

Intimal sarcoma is an exceedingly rare malignant neoplasm arising from the intimal layer of large blood vessels — most frequently the pulmonary artery, aorta, and its major branches. Categorized within the vascular tumors section of the 2020 WHO Classification of Soft Tissue and Bone Tumors, intimal sarcoma is molecularly defined in the majority of cases by MDM2 amplification, detectable by FISH or next-generation sequencing, which enables distinction from thromboembolic disease and other vascular proliferations that may mimic intimal sarcoma on imaging or gross pathology. The pulmonary artery is the most common site (approximately 60% of cases), followed by the aorta and its branches; primary cardiac intimal sarcoma, arising from the great vessels at their cardiac origin, may overlap clinically with primary cardiac sarcoma.

The diagnostic challenge posed by intimal sarcoma is profound: the intravascular and intraluminal growth pattern means these tumors present with symptoms of vascular obstruction — pulmonary hypertension, right heart failure, hemoptysis, and constitutional symptoms — that are nearly identical to chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Patients are frequently misdiagnosed with CTEPH and treated with anticoagulation for months to years before the correct diagnosis is established, often when an unexpected intraoperative or autopsy finding reveals the true nature of the intraluminal material. This diagnostic odyssey represents one of the most consequential failure modes in vascular oncology, and care technology platforms can play a critical role in surfacing diagnostic red flags that prompt earlier tissue diagnosis.

MDM2 amplification serves as a highly specific molecular marker for intimal sarcoma, present in approximately 80–90% of cases. MDM2 FISH on pulmonary endarterectomy specimens or CT-guided biopsy of accessible vascular lesions has become the standard approach for molecular confirmation. In 2026, next-generation sequencing panels that include MDM2 amplification copy number analysis, as well as RNA-seq detection of CDK4 co-amplification, have supplanted single-marker FISH in centers with access to comprehensive genomic profiling. Treatment remains primarily surgical — pulmonary endarterectomy for pulmonary artery intimal sarcoma, or en bloc resection for aortic primaries — with adjuvant or palliative chemotherapy (doxorubicin-based, gemcitabine/docetaxel) and radiation used in unresectable or recurrent disease. MDM2 amplification has also positioned intimal sarcoma as a candidate for MDM2 inhibitor trials, though clinical data in this histology remain early.

Care Technology Landscape

CTEPH-Mimicry Red Flag Detection Systems — The most critical informatics function in intimal sarcoma is early detection of cases likely to represent malignancy rather than CTEPH. Care platforms should be configured with clinical decision support rules that surface a diagnostic reconsideration alert when: (1) a CTEPH diagnosis is made in a patient under age 50, (2) pulmonary hypertension is refractory to anticoagulation with evidence of progressive intraluminal filling defects, (3) CT pulmonary angiography demonstrates soft tissue filling defects rather than organizing thrombus morphology, or (4) PET-CT demonstrates FDG avidity in pulmonary artery filling defects. These CDS triggers should prompt a malignancy workup pathway including tissue biopsy or MDM2 molecular testing on available material.

Vascular Imaging PACS Integration and Structured Reporting — CT pulmonary angiography (CTPA), cardiac MRI, and PET-CT are the primary imaging modalities in intimal sarcoma diagnosis and surveillance. PACS platforms must support structured vascular mass reporting templates that capture: intraluminal lesion morphology (soft tissue vs. organizing thrombus characteristics), FDG-avidity on PET, lesion extent relative to pulmonary valve, and right ventricular pressure estimates from echocardiography. Radiologists working at centers managing intimal sarcoma should have access to prior imaging comparisons with automated measurement extraction to detect progression at surveillance.

MDM2 Molecular Diagnostic Integration — LIS platforms must support a reflexive MDM2 testing pathway triggered by: (1) pathology report containing terms "intravascular lesion," "intimal proliferation," or "pulmonary artery specimen" in the absence of a prior malignancy diagnosis; or (2) oncologist-ordered MDM2 FISH or NGS on vascular specimens. Molecular results must flow back into the LIS and OIS as structured data — copy number value, amplification threshold, and interpretive category — not as a free-text pathology addendum, to enable automated CDS triggering.

Pulmonary Hypertension and Cardio-Oncology Co-Management — Intimal sarcoma patients are managed simultaneously by pulmonary hypertension specialists or cardiothoracic surgeons and oncology. EHR platforms must support shared care planning, synchronized hemodynamic monitoring, and real-time alert routing to both services. Right heart catheterization data — mean pulmonary artery pressure, pulmonary vascular resistance, cardiac output — must be structured and stored for longitudinal comparison, as hemodynamic progression is a primary endpoint for surgical candidacy reassessment.

Endovascular Procedure and Pulmonary Endarterectomy Coordination — Pulmonary endarterectomy for intimal sarcoma is performed at specialized centers (UCSD, Cleveland Clinic, Papworth Hospital) and requires complex logistical coordination. Care platforms must support extramural surgical referral workflows, pre-operative staging documentation packages, intraoperative specimen submission workflows for immediate MDM2 confirmation on unexpected specimens, and post-operative hemodynamic monitoring integration.

MDM2 Inhibitor Trial Matching — As MDM2 inhibitor clinical trials (navtemadlin, BI 907828, milademetan) expand their eligibility to include MDM2-amplified sarcomas, platforms must be configured to match intimal sarcoma patients with MDM2 amplification to open trials. Trial matching engines should query MDM2 amplification as a molecular eligibility criterion and surface matched trials when MDM2 confirmation data arrives in the OIS.

Key Monitoring Metrics

Diagnostic Accuracy and CTEPH Differentiation

CDS Red Flag Detection

  • CTEPH diagnosis in patient age < 50 generating malignancy workup CDS alert: alert trigger rate (target: 100%)
  • FDG-avid pulmonary artery filling defect on PET-CT generating intimal sarcoma consideration CDS alert: trigger rate (target: 100%)
  • Progressive intraluminal soft tissue morphology on CTPA generating radiologist flag for oncology review: radiology flag rate
  • Median time from initial CTEPH-mimicry presentation to malignancy workup initiation for intimal sarcoma–confirmed cases: diagnostic delay metric (institutional quality KPI)

Molecular Confirmation

  • MDM2 FISH or NGS ordered on all vascular specimens with intimal sarcoma as clinical differential: MDM2 ordering rate (target: > 90%)
  • MDM2 result returned as structured data in OIS within 10 business days of specimen submission: TAT compliance rate
  • MDM2-amplified results generating trial matching engine query within 4 hours: automated routing rate

Pathology and MTB Review

  • Expert vascular or soft tissue pathology consultation obtained within 14 days of intimal sarcoma diagnosis: consultation rate (target: 100%)
  • Cases presented at vascular oncology or sarcoma MTB within 10 days of diagnosis: MTB timeliness rate
  • MTB consensus plan documented in OIS within 48 hours of meeting: documentation timeliness rate

Vascular Imaging Surveillance

Imaging Protocol Compliance

  • Active therapy CTPA or cardiac MRI at 8-week intervals for non-resected intimal sarcoma: interval compliance rate
  • Post-resection surveillance CTPA at 3-month intervals for year 1, 6-month intervals for years 2–3: schedule compliance
  • PET-CT restaging at progression or equivocal CTPA findings: PET utilization compliance
  • Structured vascular imaging report completed within 48 hours of scan acquisition: structured reporting rate

Hemodynamic Monitoring

  • Right heart catheterization data structured and stored in OIS for all intimal sarcoma patients with pulmonary artery involvement: data completeness rate
  • Mean pulmonary artery pressure > 35 mmHg generating cardiology and surgical oncology joint alert: threshold alert rate
  • RVSP progression > 10 mmHg on serial echocardiography generating surgical candidacy reassessment trigger: reassessment trigger rate

Clinical Trial Matching and Treatment Delivery

MDM2 Inhibitor Trial Matching

  • MDM2-amplified intimal sarcoma patients matched against open MDM2 inhibitor trials within 48 hours of MDM2 confirmation: matching timeliness rate
  • Trial eligibility offer documented within 7 days of match identification: offer timeliness rate
  • Trial matching engine updated within 7 days of new MDM2-targeted trial opening: engine currency compliance

Systemic Therapy Safety

  • Doxorubicin cycles administered with cumulative dose tracking and cardiotoxicity threshold alert at 400 mg/m²: threshold alert compliance
  • Grade ≥ 3 pulmonary toxicity (hemoptysis, respiratory failure) generating emergent oncology and pulmonology dual alert: dual-service alert rate
  • Anticoagulation status documented and reconciled at each oncology encounter for patients with intravascular tumor burden: documentation compliance

Thromboembolic Event Surveillance

Thromboembolic Complication Monitoring

  • Acute pulmonary embolism on surveillance imaging generating emergent alert to both oncology and pulmonary/vascular team: dual-service alert timeliness (target: < 1 hour from report sign-out)
  • New systemic embolic event (stroke, limb ischemia) in intimal sarcoma patient generating vascular surgery consultation order: consultation trigger rate
  • D-dimer trending > 2× baseline generating imaging order trigger in patients with known intraluminal tumor: lab-triggered imaging compliance

Post-Surgical Monitoring

  • Post-pulmonary endarterectomy hemodynamic monitoring active in ICU for minimum 72 hours: monitoring activation compliance
  • Post-operative MDM2 confirmation result integrated in OIS within 5 business days of specimen sign-out: result integration timeliness
  • Adjuvant chemotherapy initiation within 8 weeks of resection for high-risk pathologic features: initiation timeliness rate

Platform Setup

Observability Architecture for Intimal Sarcoma Platforms

# Prometheus scrape config for intimal sarcoma care platforms
scrape_configs:
  - job_name: cteph_mimic_cds_engine
    static_configs:
      - targets: ['cds-vascular.internal:9090']
    scrape_interval: 30s
    metric_relabel_configs:
      - source_labels: [cds_rule_group]
        regex: 'cteph_malignancy_redflags|intimal_sarcoma_screen'
        action: keep

  - job_name: mdm2_molecular_routing
    static_configs:
      - targets: ['lis-molecular.internal:9090']
    scrape_interval: 30s

  - job_name: vascular_imaging_pipeline
    static_configs:
      - targets: ['pacs-vascular.internal:9090']
    scrape_interval: 60s

  - job_name: hemodynamic_monitoring_gateway
    static_configs:
      - targets: ['rh-cath-gateway.internal:9090']
    scrape_interval: 10s

  - job_name: mdm2_trial_matching_engine
    static_configs:
      - targets: ['trial-match-mdm2.internal:9090']
    scrape_interval: 60s

CTEPH Red Flag CDS Canary

# Pseudocode: CTEPH malignancy red flag CDS canary
def run_cteph_red_flag_canary():
    test_patient_id = "CANARY-INTIMAL-001"
    inject_patient_scenario(
        patient_id=test_patient_id,
        diagnosis="chronic_thromboembolic_pulmonary_hypertension",
        age=38,
        imaging_findings="progressive_intraluminal_soft_tissue_filling_defect",
        pet_fdg_avid=True,
        anticoagulation_refractory=True
    )
    start = time.now()
    cds_alert = poll_for_cds_alert(
        patient_id=test_patient_id,
        alert_type="cteph_malignancy_red_flag",
        timeout=3600  # 1 hour
    )
    latency = time.now() - start
    metrics.record("cteph_red_flag_cds_latency_seconds", latency)
    if cds_alert is None:
        page_on_call("Intimal sarcoma canary: CTEPH malignancy red flag CDS not firing for canary patient")

MDM2 Molecular Routing Monitor

# Pseudocode: MDM2 structured result routing monitor
def monitor_mdm2_routing():
    recent_mdm2_results = query_lis_results(
        test_name="MDM2_FISH",
        result_age_hours_max=24
    )
    for result in recent_mdm2_results:
        ois_structured = check_ois_structured_field(
            patient_id=result.patient_id,
            field="mdm2_amplification_status"
        )
        if ois_structured is None:
            create_informatics_alert(
                patient_id=result.patient_id,
                message="MDM2 result available in LIS but not structured in OIS alteration field",
                priority="P2"
            )
        if result.amplified and not check_trial_match_generated(result.patient_id):
            alert_informatics_team(
                f"MDM2-amplified intimal sarcoma patient {result.patient_id}: trial match not generated within 4-hour SLA"
            )
    metrics.record("mdm2_routing_compliance", compliance_rate(recent_mdm2_results))

Pulmonary Artery Pressure Threshold Alert

-- Alert on elevated mean pulmonary artery pressure in intimal sarcoma patients
CREATE TRIGGER pap_threshold_intimal_sarcoma
AFTER INSERT ON hemodynamic_measurements
FOR EACH ROW
WHEN NEW.measurement_type = 'mean_pulmonary_artery_pressure'
  AND NEW.value > 35
  AND EXISTS (
    SELECT 1 FROM patients
    WHERE patient_id = NEW.patient_id
      AND diagnosis ILIKE '%intimal sarcoma%'
  )
EXECUTE PROCEDURE dual_service_hemodynamic_alert(
  patient_id := NEW.patient_id,
  measurement_value := NEW.value,
  alert_type := 'elevated_mean_pap_intimal_sarcoma',
  recipient_services := ARRAY['cardiology', 'surgical_oncology']
);

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • CTEPH red flag CDS engine offline; malignancy reconsideration alerts not firing for any new CTEPH diagnoses in high-risk age group
  • Hemodynamic monitoring gateway offline; right heart catheterization data not reaching OIS for active intimal sarcoma patients
  • Acute pulmonary embolism alert system not generating dual-service notification for intimal sarcoma patients
  • Post-pulmonary endarterectomy ICU monitoring integration failing within 72-hour post-operative window

P2 — Degraded Operation

  • MDM2 molecular routing compliance below 90% (results not structured in OIS within 24 hours of LIS sign-out)
  • MTB presentation rate below 90% for newly diagnosed intimal sarcoma within 10-day target
  • MDM2 inhibitor trial matching latency exceeding 48 hours for > 5% of confirmed MDM2-amplified cases
  • Mean pulmonary artery pressure threshold alert not generated for > 1 patient in monthly hemodynamic audit
  • Surveillance CTPA schedule compliance below 85% for post-treatment cohort in quarterly review

P3 — Quality and Compliance

  • Expert pathology consultation rate below 90% for new intimal sarcoma diagnoses: consultation audit
  • Structured vascular imaging report rate below 85% for CTPA and cardiac MRI in monthly radiology audit
  • MDM2 test ordering rate below 85% for vascular intraluminal specimens: LIS workflow gap review

On-Call Escalation

  • Clinical informatics engineer (primary for P1 CDS engine, hemodynamic gateway, and molecular routing failures)
  • Cardiology or pulmonary hypertension on-call (for out-of-hours hemodynamic threshold and acute PE alerts)
  • Surgical oncology or vascular surgery on-call (for P1 acute hemodynamic decompensation in post-endarterectomy patients)

Notification Channels

  • P1: PagerDuty page + SMS to informatics, cardiology, and surgical oncology on-call simultaneously
  • P2: Slack #intimal-sarcoma-informatics channel + email to vascular oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog queue

Conclusion

Intimal sarcoma imposes a uniquely demanding informatics challenge: the disease mimics a common benign condition so effectively that the greatest clinical risk is not treatment failure but diagnostic failure. Care technology platforms that do not actively surface CTEPH-mimicry red flags — young patient age, FDG-avid intraluminal disease, progressive soft tissue morphology, anticoagulation refractoriness — will silently enable the diagnostic delays that define the natural history of this disease at most institutions. The informatics case for CTEPH malignancy CDS rules is therefore not incremental quality improvement but a structural intervention against a well-characterized diagnostic failure mode.

Beyond diagnosis, intimal sarcoma demands hemodynamic monitoring infrastructure at the intersection of vascular critical care and oncology, molecular routing that surfaces MDM2 amplification as a structured CDS trigger for both tumor-agnostic therapy and emerging MDM2 inhibitor trials, and vascular imaging surveillance automation that maintains post-treatment vigilance for a patient population that has often had months of diagnostic odyssey before reaching appropriate oncologic care. Engineering teams responsible for intimal sarcoma informatics should treat the CTEPH red flag CDS engine and hemodynamic monitoring gateway as P1 infrastructure, build MDM2 molecular routing into the standard vascular pathology workflow, and invest in the cross-specialty alert routing that this disease demands. With this infrastructure in place, care technology can meaningfully shorten the diagnostic delay that remains the dominant obstacle to improved outcomes in intimal sarcoma.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles